Plural Ring Hetero Atoms In The Bicyclo Ring System, Or Ring Nitrogen Is Shared By The Two Cyclos Of The Bicyclo Ring System Patents (Class 548/453)
-
Publication number: 20130196960Abstract: The present disclosure relates to compounds useful as agonists of cannabinoid receptors. The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment of various disorders either alone or in combination therapy.Type: ApplicationFiled: February 9, 2011Publication date: August 1, 2013Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Jason Rohde, Charles Kim, Takashi Nakai, Galen John Carey
-
Publication number: 20130196978Abstract: Alkaloid aminoester compounds which act as muscarinic receptor antagonists are useful for the prevention and/or treatment of a broncho-obstructive or inflammatory diseases.Type: ApplicationFiled: March 14, 2013Publication date: August 1, 2013Applicant: Chiesi Farmaceutici S.p.A.Inventor: Chiesi Farmaceutici S.p.A.
-
Publication number: 20130197008Abstract: There is provided a compound of Formula I(a) or I(b): or a pharmaceutically acceptable salt thereof, wherein the various substitutents are defined herein.Type: ApplicationFiled: September 14, 2012Publication date: August 1, 2013Applicant: Pfizer Inc.Inventors: Robert O. HUGHES, Rajesh V. Devraj, Donald J. Rogier, John I. Trujillo, Steve R. Turner, Wei Huang
-
Patent number: 8497381Abstract: Described herein are compounds that are antagonists of PGD2 receptors. Also described are pharmaceutical compositions and medicaments that include the antagonists of PGD2 receptors described herein, as well as methods of using such antagonists of PGD2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.Type: GrantFiled: February 25, 2009Date of Patent: July 30, 2013Assignee: Panmira Pharmaceuticals, LLCInventors: John Howard Hutchinson, Brian Andrew Stearns, Thomas Jonathan Seiders, Jill Melissa Scott, Jeannie M. Arruda, Bowei Wang
-
Publication number: 20130190288Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, A, X1, X2, X3, X4, R1, R2, R3a, R3b, R4a and R4b are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.Type: ApplicationFiled: December 18, 2012Publication date: July 25, 2013Applicant: GENENTECH, INC.Inventor: Genentech, Inc.
-
Patent number: 8492427Abstract: The invention relates to isoindolones of formula, (I) with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.Type: GrantFiled: July 1, 2009Date of Patent: July 23, 2013Assignee: Genentech, Inc.Inventors: Emanuela Gancia, Robert Andrew Heald, Philip Jackson, Stephen Price
-
Publication number: 20130180589Abstract: The present invention relates to organic photovoltaic cell materials and components and particularly, to the organic photovoltaic cell materials and the components with high optical conversion efficiency, simple preparation process and low cost. The chemical formula of the materials is represented by chemical formula (I): where n is a natural number and X is the following chemical formula (II): where m is 1˜3 and A is hydrogen, fluorine, chlorine, C1˜C18-alkyl, thienyl, phenyl or pyridyl in which thienyl, phenyl or pyridyl may be substituted with C1˜C18-alkyl in any position.Type: ApplicationFiled: April 3, 2012Publication date: July 18, 2013Applicant: LUMINESCENCE TECHNOLOGY CORPORATIONInventors: Feng-Wen YEN, Cheng-Hao CHANG, Chin-Min TENG
-
Publication number: 20130178457Abstract: Compounds of Formula (I) along with processes for their preparation that are useful for treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors. Methods of treating, managing and/or lessening the diseases, disorders, syndromes or conditions associated with the modulation of cannabinoid (CB) receptors of Formula (I).Type: ApplicationFiled: July 5, 2012Publication date: July 11, 2013Applicant: LUPIN LIMITEDInventors: Sanjeev Anant KULKARNI, Sachin MADAN, Nirmal Kumar JANA, Prashant Vitthalrao TALE, Narasimha Murthy CHEEMALA, Sachin Jaysing MAHANGARE, Prashant Popatrao VIDHATE, Chaitanya Prabhakar KULKARNI, Sapana Suresh PATEL, Amolsing Dattu PATIL, Seema Prabhakar ZADE, Rohan Mahadev SHINDE, Venkata P. PALLE, Rajender Kumar KAMBOJ
-
Publication number: 20130178500Abstract: Hexahydropyrrolo[3,4-b]pyrrole derivatives, preparation methods and pharmaceutical uses thereof are provided. Specifically, dipeptidyl peptidase IV inhibitors presented by following formula (I) are provided. Such compounds can be used for treating or preventing the diseases associated with dipeptidyl peptidase IV, such as diabetes, obesity and hyperlipemia. The compounds presented by formula (I) and pharmaceutically acceptable salts thereof, a method for preparing a pharmaceutical composition thereof and their uses in the manufacture of medicaments for treating or preventing the disease associated with dipeptidyl peptidase IV are provided.Type: ApplicationFiled: November 26, 2012Publication date: July 11, 2013Inventors: Peng Lu, Rui Zhang, Wansong Yu, Mingjie Zhu, Yilang Chen
-
Publication number: 20130178453Abstract: The present disclosure relates to compounds useful as agonists of the cannabinoid receptors. The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment of various disorders, either alone or in combination therapy. The compounds of the invention have Formula (I).Type: ApplicationFiled: February 9, 2011Publication date: July 11, 2013Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Jason Rohde, Bo Peng, Takashi Nakai, Kevin Sprott, Ara Mermerían, Wayne C. Schairer, Galen John Carey
-
Publication number: 20130172575Abstract: The present invention relates to compounds of the formula I wherein the substituents are as defined in claim 1, and their use as organic semiconductor in organic devices, like diodes, organic field effect transistors and/or a solar cells. The compounds of the formula I have excellent solubility in organic solvents. High efficiency of energy conversion, excellent field-effect mobility, good on/off current ratios and/or excellent stability can be observed, when said compounds are used in semiconductor devices or organic photovoltaic (PV) devices (solar cells).Type: ApplicationFiled: February 26, 2013Publication date: July 4, 2013Applicant: BASF SEInventor: BASF SE
-
Patent number: 8466191Abstract: Compounds represented by Formula (I) or Formula (II) against cell releasing TNF?, their pharmaceutically acceptable salts or hydrates and preparation methods and uses thereof, in which A and B represent CH2, CO, SO, or SO2; D represents S, NH, or NC1-6 alkyl; R1 represents H, or one or two same or different radical(s) selected from the group consisting of F, Cl, Br, C1-4 alkyl, OH, OC1-4 alkyl, NO2, NHC(O)C1-4 alkyl, NH2, NH(C1-4 alkyl), or N(C1-4 alkyl)2.Type: GrantFiled: October 16, 2007Date of Patent: June 18, 2013Inventor: Hesheng Zhang
-
Patent number: 8461352Abstract: The present invention relates to a process for preparing azabicyclic compounds that are useful intermediates for synthesizing pharmaceutical compounds or salts thereof.Type: GrantFiled: March 9, 2012Date of Patent: June 11, 2013Assignee: Vertex Pharmaceuticals IncorporatedInventors: Narendra Bhalchandra Ambhaikar, Brian Richard Bear, Lev T. D. Fanning, Robert Hughes, Benjamin Littler
-
Patent number: 8450341Abstract: The present disclosure is directed to new inhibitors of the p38 mitogen-activated protein kinase having the general formula (I), processes for preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.Type: GrantFiled: April 16, 2009Date of Patent: May 28, 2013Assignee: Almirall, S.A.Inventors: Paul Robert Eastwood, Jacob Gonzalez Rodriguez, Victor Giulio Matassa
-
Publication number: 20130129811Abstract: The present invention provides a cationic lipid, which allow nucleic acids to be easily introduced into cells, represented by formula (I) (wherein: R1 and R2 are, the same or different, each (Z)-pentadecenyl, (Z)-hexadecenyl or (Z)-heptadecenyl, etc, a and b are, the same or different, each 0 to 3, m is 1, the dotted line is a single bond or absent, X1 and X2 are hydrogen atoms, or are combined together to form a single bond or alkylene, X4 is absent or is alkylene, etc X3 is absent or is alkyl, etc, Y is absent or anion, L3 is a single bond, —CO—O— or —O—CO— R3 is hydrogen atoms, alkyl, etc, L1 and L2 are —O—, —CO—O— or —O—CO—) and the like.Type: ApplicationFiled: April 28, 2011Publication date: May 23, 2013Inventors: Takeshi Kuboyama, Tomohiro Era, Tomoyuki Naoi
-
Publication number: 20130131034Abstract: The instant invention relates to derivatives of formula (I) and their application in therapeutics.Type: ApplicationFiled: March 1, 2011Publication date: May 23, 2013Applicant: SANOFIInventors: Markus Follmann, Pascale Goberville, Stéphanie Hachtel, Gerhard Hessler, Heinz-Werner Kleemann, Thomas Maier, Gary MC Cort, Carsten Struebing, Bérangère Thiers, Li-Hsing Wang
-
Publication number: 20130123243Abstract: This invention is directed to compounds of formula (I): where r, q, R, R2, R3, R4, R5a, R5b, R5c, R6a, R6b, R6c, R7, R8, and R9 are described herein, as single stereoisomers or as mixtures of stereoisomers, or pharmaceutically acceptable salts, solvates, clathrates, polymorphs, ammonium ions, N-oxides or prodrugs thereof; which are leukotriene A4 hydrolase inhibitors and therefore useful in treating inflammatory disorders. Pharmaceutical compositions comprising the compounds of the invention and methods of preparing the compounds of the invention are also disclosed.Type: ApplicationFiled: October 18, 2012Publication date: May 16, 2013Inventor: Celtaxsys, Inc.
-
Publication number: 20130123285Abstract: The present invention provides an assay for screening any agent that modulates the ability of A3G to bind with RNA. The invention provides an agent identified by high throughput screening methods and methods of treatment using the identified agent as a means of inhibiting HIV infection and reducing the emergence of viral drug-resistance.Type: ApplicationFiled: May 13, 2011Publication date: May 16, 2013Applicant: UNIVERSITY OF ROCHESTERInventors: Harold C. Smith, Kimberly Prohaska, William M. McDougall
-
Publication number: 20130116216Abstract: Certain compounds and pharmaceutically acceptable salts are provided herein. Also provided are pharmaceutical compositions comprising at least one compound or pharmaceutically acceptable salt therein and one or more pharmaceutically acceptable vehicle. Methods of treating patients suffering from certain disease states responsive to the inhibition of transglutaminase TG2 activity are described. These disease states include neurodegenerative disorders such as Huntington's disease. Also described are methods of treatment include administering at least one compound or pharmaceutically acceptable salt thereof as a single active agent or administering at least one compound or pharmaceutically acceptable salt thereof in combination with one or more other therapeutic agents.Type: ApplicationFiled: November 12, 2010Publication date: May 9, 2013Inventors: Celia Dominguez, John Wityak, Michael Prime, Stephen Martin Courtney, Christopher Yarnold, Frederick Brookfield, Richard Marston, Douglas Macdonald
-
Publication number: 20130116232Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.Type: ApplicationFiled: June 8, 2011Publication date: May 9, 2013Applicant: ARAGON PHARMACEUTICALS, INC.Inventors: Mehmet Kahraman, Steven P. Govek, Johnny Y. Nagasawa, Nicholas D. Smith
-
Patent number: 8435341Abstract: A method of preparing a pigment includes in order the steps of: a) providing a pigment containing a nucleophile group under basic conditions; b) reacting the pigment with 1,4-butane sultone or 1,3-propane sultone in an alkaline medium to form sulfobutyl groups respectively sulfopropyl groups on the pigment surface; and c) adding acid to convert the sulfobutyl groups or sulfopropyl groups to sulfonic acid groups. Pigments obtainable by the method and non aqueous pigment dispersions are also disclosed.Type: GrantFiled: October 20, 2010Date of Patent: May 7, 2013Assignee: AGFA-Gevaert N.V.Inventor: Geert Deroover
-
Publication number: 20130108685Abstract: The present invention provides a cationic lipid, which allow nucleic acids to be easily introduced into cells, represented by formula (I) (wherein: R1 and R2 are, the same or different, alkenyl, etc, and X1 and X2 are hydrogen atoms, or are combined together to form a single bond or alkylene, and X3 is absent or is alkyl, etc, Y is absent or anion, a and b are, the same or different, 0 to 3, and L3 is a single bond, etc, R3 is alkyl, etc, L1 and L2 are —O—, —CO—O— or —O—CO—), a composition comprising the cationic lipid and a nucleic acid, and a method for introducing a nucleic acid into a cell by using the composition comprising the cationic lipid and the nucleic acid, and the like.Type: ApplicationFiled: April 28, 2011Publication date: May 2, 2013Inventors: Takeshi Kuboyama, Tomohiro Era, Tomoyuki Naoi
-
Publication number: 20130109668Abstract: Provided are compounds of Formula I, R1-L1-A-L2-R2??(I), and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein A, L1, L2, R1 and R2 are defined herein. The present invention also provides a pharmaceutical composition and methods of using such compounds. The compounds are useful for therapy and/or prophylaxis in a patient, and in particular to inhibitors of Soluble Epoxide Hydrolase (sEH).Type: ApplicationFiled: October 26, 2012Publication date: May 2, 2013Applicant: Hoffmann-La Roche Inc.Inventor: Hoffmann-La Roche Inc.
-
Publication number: 20130109721Abstract: The present disclosure relates to N-benzyl pyrrole compounds of formula (I) useful as inhibitors of the enzyme Fatty Acid Amide Hydrolase (FAAH). The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment or prevention of various disorders.Type: ApplicationFiled: December 8, 2010Publication date: May 2, 2013Applicant: Ironwood Pharmaceuticals, Inc.Inventors: Kevin Sprott, John Jeffrey Talley, Jane Yang, Bo Peng
-
Patent number: 8415486Abstract: The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.Type: GrantFiled: May 27, 2010Date of Patent: April 9, 2013Assignee: TetraLogic Pharmaceuticals Corp.Inventors: Stephen M. Condon, Yijun Deng, Matthew D. Alexander, Matthew G. Laporte
-
Publication number: 20130085256Abstract: Described herein are compositions including heterocyclic organic compounds based on fused thiophene compounds, polymers based on fused thiophene compounds, and methods for making the monomers and polymer along with uses in thin film-based and other devices.Type: ApplicationFiled: October 31, 2012Publication date: April 4, 2013Inventors: Mingqian He, Jianfeng Li, James Robert Matthews, Weijun Niu, Arthur L. Wallace
-
Patent number: 8404736Abstract: The invention relates to compounds of Formula (I) (or pharmaceutically acceptable salts thereof) as defined herein, pharmaceutical compositions thereof, and their use in manufactures and methods for modulating biological processes including antagonism of Prostaglandin EP4 receptor as a therapeutic treatment.Type: GrantFiled: August 13, 2009Date of Patent: March 26, 2013Assignee: Beta Pharma Canada Inc.Inventor: Wei Yuan
-
Patent number: 8404864Abstract: The present invention relates to compounds of the formula (I) wherein the substituents are as defined in claim 1, and their use as organic semiconductor in organic devices, like diodes, organic field effect transistors and/or a solar cells. The compounds of the formula I have excellent solubility in organic solvents. High efficiency of energy conversion, excellent field-effect mobility, good on/off current ratios and/or excellent stability can be observed, when said compounds are used in semiconductor devices or organic photovoltaic (PV) devices (solar cells).Type: GrantFiled: September 22, 2008Date of Patent: March 26, 2013Assignee: BASF SEInventors: Zhimin Hao, Beat Schmidhalter, Jean-Luc Budry, Margherita Fontana, Mathieu Turbiez, Frank Bienewald, Mathias Düggeli, Oliver Frédéric Aebischer, Pascal Hayoz, Marta Fonrodona Turon
-
Patent number: 8404865Abstract: The present invention relates to a process for preparing azabicyclic compounds that are useful intermediates for synthesizing pharmaceutical compounds or salts thereof.Type: GrantFiled: September 17, 2010Date of Patent: March 26, 2013Assignee: Vertex PharmaceuticalsInventors: Narendra Bhalchandra Ambhaikar, Brian Richard Bear, Lev T. D. Fanning, Robert Hughes, Benjamin Littler
-
Patent number: 8399683Abstract: The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.Type: GrantFiled: September 16, 2009Date of Patent: March 19, 2013Assignee: TetraLogic PharmaceuticalsInventors: Stephen M. Condon, Matthew G. Laporte
-
Publication number: 20130059898Abstract: Muscarinic acetylcholine receptor antagonists and methods of using them for the treatment of muscarinic acetyl-choline receptor-mediated diseases, such as pulmonary diseases, are provided.Type: ApplicationFiled: January 27, 2011Publication date: March 7, 2013Applicant: Theron Pharmaceuticals, Inc.Inventors: Jürg R. Pfister, Gwenaella Rescourio, Meenakshi S. Venkatraman, Xiaoming Zhang
-
Patent number: 8389564Abstract: Disclosed herein are compounds of Formula (I) that include a sulfonate ester, ester or ether group. Compounds of Formula (I) can be included in pharmaceutical compositions, and can be used to treating and/or ameliorating a disease or condition, such as cancer, a microbial disease and/or inflammation.Type: GrantFiled: May 14, 2012Date of Patent: March 5, 2013Inventors: Venkat Rami Reddy Macherla, Barbara Christine Potts, Rama Rao Manam, Katherine A. McArthur, Ta-Hsiang Chao, Saskia Theodora Cornelia Neuteboom
-
Patent number: 8383665Abstract: Isolated immunomodulatory (e.g. immunostimulatory) polyhydroxlated pyrrolizidine compounds having the formula are disclosed. In these compounds R is selected from hydrogen, straight or branched, unsubstituted or substituted, saturated or unsaturated acyl, alkyl (e.g. cycloalkyl), alkenyl, alkynyl and aryl groups. The compounds are useful in therapy and prophylaxis, including increasing the Th1:Th2 response ratio, hemorestoration, alleviation of immunosuppression, cytokine stimulation, treatment of proliferative disorders (e.g. cancer), vaccination, stimulation of the innate immune response and boosting of the activity of endogenous NK cells.Type: GrantFiled: January 21, 2004Date of Patent: February 26, 2013Assignee: Summit (Wales) LimitedInventors: Alison Ann Watson, Robert James Nash, Emma Louisa Evinson
-
Publication number: 20130029970Abstract: The present disclosure relates to compounds of formula I useful as agonists of cannabinoid receptors. The disclosure also provides pharmaceutically acceptable compositions comprising the compounds of the disclosure and methods of using the compositions in the treatment of various disorders.Type: ApplicationFiled: July 9, 2010Publication date: January 31, 2013Applicant: IRONWOOD PHARMACEUTICALS, INCInventors: Kevin Sprott, Jason Rohde, Takashi Nakai, Bo Peng, John Jeffrey Talley
-
Patent number: 8344160Abstract: The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R1, R4, R5, R3, R3a, W, D, R2a, R2b and R2c are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression, anxiety or intestinal inflammation, by administration of a therapeutically effective dose of a compound according to Formula I.Type: GrantFiled: October 8, 2009Date of Patent: January 1, 2013Assignee: Bristol-Myers Squibb CompanyInventors: Guohua Zhao, William N. Washburn, James J. Mignone
-
Patent number: 8344147Abstract: The present invention relates to processes for preparing solid state forms of N-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1, 4-dihydroquinoline-3-carboxamide, including Compound 1 Form A, Compound 1 Form A-HCl, Compound 1 Form B, and Compound 1 Form B-HCl, any combination of these forms, pharmaceutical compositions thereof, and methods of treatment therewith.Type: GrantFiled: October 21, 2010Date of Patent: January 1, 2013Assignee: Vertex Pharmaceutical IncorporatedInventors: Narendra Bhalchandra Ambhaikar, Robert Hughes, Dennis James Hurley, Elaine Chungmin Lee, Benjamin Littler, Mehdi Numa, Stefanie Roeper, Urvi Sheth
-
Publication number: 20120329773Abstract: This invention relates to bicyclic ring system substituted amide functionalized phenols of general formula 1, their use as inhibitors of CXCR2 activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin, or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.Type: ApplicationFiled: December 13, 2011Publication date: December 27, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Riccardo GIOVANNINI, Dieter HAMPRECHT, Barbara KISTLER, Iain LINGARD
-
Publication number: 20120298976Abstract: There is presently provided organic compounds of formula I, n-type acceptor materials derived from such compounds and devices comprising such n-type acceptor materials.Type: ApplicationFiled: October 22, 2009Publication date: November 29, 2012Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Prashant Sonar, Richard Yee Cheong Shin Koy Sien, Zhikuan Chen, Kok Haw Ong, Ging Meng Ng, Achmad Zen
-
Publication number: 20120302523Abstract: A method of making an endoperoxide from a diene and oxygen in the presence of a photocatalyst having an excited state lifetime of at least 100 nanoseconds, the endoperoxide being represented by the formula: where R1 is an aryl substituted with at least one group selected from the group consisting of alkoxy, hydroxyl, halogen, carbamate, sulfonamide, silyloxy, amide, and combinations thereof or a substituted or unsubstituted heteroaryl, R2 is hydrogen, alkyl, alkynyl, or aryl, R3 is hydrogen, alkyl, alkynyl, or aryl, R4 is alkynyl or aryl, R5 is hydrogen or a substituent, R6 is hydrogen or a substituent, and A1, A2, and A3 are the same or different atoms and form a divalent group that combines with the two carbon atoms of the endoperoxide ring to form a saturated or unsaturated, substituted or unsubstituted ring system of a size of from five to six atoms.Type: ApplicationFiled: May 27, 2011Publication date: November 29, 2012Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Tehshik P. Yoon, Jonathan D. Parrish, Michael A. Ischay
-
Patent number: 8318052Abstract: The present invention relates to a pigment composition composed of compounds of the formula (I), (II) and (III) with a novel crystal modification, to their preparation and to the use of this novel product as a pigment. For many applications of organic pigments, for example the coloring of metallic lacquers or the use thereof in color filters, a very high transparency is required. To produce color filters, for example, particularly fine pigments are used, in order to substantially rule out the particle scattering which leads to a lowering of the contrast ratio. The commercially available products, however, do not always meet all requirements of the art. More particularly, there was a need for improvement with regard to the transparency and the associated fineness of the pigment crystals, and also the color purity (chroma).Type: GrantFiled: January 17, 2008Date of Patent: November 27, 2012Assignee: Clariant Finance (BVI) LimitedInventor: Matthias Ganschow
-
Publication number: 20120295934Abstract: The invention provides novel compounds having the general formula (I) wherein R1, R2, A, E, G and n are as described herein, compositions including the compounds and methods of using the compounds. The compounds are useful as inhibitors of hormone sensitive lipase (HSL) and may be used for the treatment of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis, obesity, cardiovascular diseases, myocardial dysfunction, inflammation, non-alcoholic fatty liver disease or non-alcoholic steatohepatitis.Type: ApplicationFiled: May 4, 2012Publication date: November 22, 2012Inventors: Aurelia Conte, Daniel Hunziker, Werner Neidhart, Matthias Nettekoven, Tanja Schulz-Gasch
-
Patent number: 8314120Abstract: The present invention relates to small molecule potentiators of metabotropic receptors, in particular of the mGlu2 receptor. The present invention also relates to the use of these compounds for the prevention or treatment of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved.Type: GrantFiled: March 28, 2011Date of Patent: November 20, 2012Assignee: Abbott GmbH & Co. KGInventors: Wilfried Braje, Katja Jantos, Hervé Geneste, Mario Mezler, Margaretha Henrica Maria Bakker
-
Publication number: 20120283447Abstract: Provided is a method for producing a nanoparticle. Provided especially is, in the method for producing a nanoparticle to separate a diketopyrrolopyrrole pigment, a method for separating an ?-type diketopyrrolopyrrole pigment nanoparticle having high crystallinity by carrying out separation of the diketopyrrolopyrrole pigment and crystal type transformation to the ?-type with substantially a single step. The ?-type diketopyrrolopyrrole pigment nanoparticle is separated by mixing a diketopyrrolopyrrole pigment solution having the diketopyrrolopyrrole pigment dissolved in a solvent and an alcohol solvent containing an alcohol compound solvent in a thin film fluid formed between at least two processing surfaces 1 and 2 arranged to be opposite to each other so as to be able to approach to and separate from each other, at least one of which rotates relative to the other.Type: ApplicationFiled: February 1, 2011Publication date: November 8, 2012Inventor: Masakazu Enomura
-
Publication number: 20120270919Abstract: Disclosed herein are compounds of Formula (I) that include a sulfonate ester, ester or ether group. Compounds of Formula (I) can be included in pharmaceutical compositions, and can be used to treating and/or ameliorating a disease or condition, such as cancer, a microbial disease and/or inflammation.Type: ApplicationFiled: May 14, 2012Publication date: October 25, 2012Applicant: Nereus Pharmaceuticals, Inc.Inventors: Venkat Rami Reddy Macherla, Barbara Christine Potts, Rama Rao Manam, Katherine A. McArthur, Ta-Hsiang Chao, Saskia Theodora Cornelia Neuteboom
-
Patent number: 8293924Abstract: An improved process for the preparation of carbapenem antibiotic of formula (I) or its hydrate is provided.Type: GrantFiled: September 30, 2008Date of Patent: October 23, 2012Assignee: Orchid Chemicals & Pharmaceuticals LimitedInventors: Senthilkumar Udayampalayam Palanisamy, Mohan Singaravel, Vignesh Babu Heeralal
-
Publication number: 20120264906Abstract: Disclosed are molecular and polymeric compounds having desirable properties as semiconducting materials. Such compounds can exhibit desirable electronic properties and possess processing advantages including solution-processability and/or good stability. Organic transistor and photovoltaic devices incorporating the present compounds as the active layer exhibit good device performance.Type: ApplicationFiled: March 23, 2012Publication date: October 18, 2012Inventors: Tobin J. Marks, Antonio Facchetti, Pierre-Luc Boudreault, Hiroyuki Miyauchi
-
Patent number: 8273269Abstract: A composition, for producing dispersions, thermoplastic masses and/or color filters, comprising (a) a colorant of formula (1) wherein 20-100 mol % R1 are Br and 80-100 mol % R3 are H, especially of formula (Ib) and/or (Ic); (b) from 0 to 150% by weight, based on (a), of C. I. Pigment Red 144, 188, 190, 224, 242 or 2,4,6-trimethylphenylperylene diimide; (c) from 3 to 25% by weight, based on (a), of a di- or tri-azacyclopentylmethyl-substituted colorant (formulae given); (d) from 0 to 10% by weight, preferably from 0.01 to 8% by weight, based on the sum of (a) and (b), of an additionally sulfonated colorant of the same kernels as in (c); and (e) from 0 to 30% by weight, preferably from 3 to 25% by weight, especially from 5 to 20% by weight, based on (a), of a diketopyrrolopyrrole colorant substituted by at least one chain containing a plurality of nitrogen atoms (cf. formula (V)).Type: GrantFiled: May 5, 2009Date of Patent: September 25, 2012Assignee: BASF SEInventors: Roman Lenz, Gerardus De Keyzer, Mathias Duggeli, Patrick Christopher Holzhuter
-
Publication number: 20120225922Abstract: The invention includes an amount of (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl phenylcarbamate for administering to a subject and also a method of preventing or treating neurotoxicity or neurodegenerative processes in a subject in need thereof using the amount thereof.Type: ApplicationFiled: March 4, 2011Publication date: September 6, 2012Inventor: Maria Maccecchini
-
Patent number: 8258176Abstract: The invention discloses a dithiolopyrrolone compound represented by formula I or its pharmaceutically acceptable salts, wherein X1, R1, R2, R3, R4 are defined as in the description. The invention also discloses the preparation of such compounds, and the use of such compounds in preparation of medicaments for increasing peripheral white blood cells and in preparation of ancillary medicaments for inhibiting the decrease of peripheral white blood cells in radiotherapy or chemotherapy.Type: GrantFiled: August 29, 2008Date of Patent: September 4, 2012Assignees: Shanghai Institute of Pharmaceutical Industry, Shanghai Modern Pharmaceutical Co., Ltd.Inventors: Guoping Wang, Quanhai Liu, Haiyan Sun, Wei Wu, Jian Hou, Lin Yao, Chungang Li, Minyu Liu, Fei Li, Xuejun Wu, Shuai Zhao
-
Publication number: 20120220602Abstract: Compounds of the formula II: wherein R2 is the side chain of leucine, isoleucine, cyclohexylglycine, O-methyl threonine, 4-fluoroleucine or 3-methoxyvaline; R3 is H, methyl or F; Rq is trifluoromethyl and Rq? is H or Rq and Rq? define keto; Q is a p-(C1-C6alkylsulphonyl)phenyl- or an optionally substituted 4-(C1-C6alkyl)piperazin-1-yl-thiazol-4-yl- moiety have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin K, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.Type: ApplicationFiled: May 10, 2012Publication date: August 30, 2012Applicant: Medivir ABInventors: Magnus Nilsson, Lourdes Oden, Pia Kahnberg, Urszula Grabowska